CollPlant Biotechnologies (CLGN) Net Cash Flow (2018 - 2025)
CollPlant Biotechnologies' (CLGN) quarterly Net Cash Flow came in at -$2.9 million in Q4 2025, up 16.24% YoY from -$2.5 million in Q4 2024, and down 2.5% on a QoQ basis from -$2.9 million in Q3 2025.
CollPlant Biotechnologies (CLGN) Net Cash Flow (2018 - 2025) Analysis & Trends
CollPlant Biotechnologies (CLGN) has 8 years of Net Cash Flow data on file, last reported at -$2.9 million in Q4 2025.
- Quarterly Net Cash Flow rose 16.24% year-over-year to -$2.9 million in Q4 2025, while the trailing twelve-month figure through Mar 2026 was -$8.3 million (up 26.79% YoY) and the FY2025 annual result came in at -$6.3 million, up 56.62% from the prior year.
- Net Cash Flow fell to -$2.9 million in Q4 2025, from -$2.9 million in the prior quarter.
- In the past five years, Net Cash Flow ranged from a high of $28.1 million in Q1 2022 to a low of -$33.8 million in Q4 2021.
- A 5-year average of -$1.6 million and a median of -$2.9 million in 2025 frame the typical range for Net Cash Flow.
- The widest YoY moves for Net Cash Flow: up 616.82% in 2021, down 579.94% in 2021.
- Tracing CLGN's Net Cash Flow over 5 years: stood at -$33.8 million in 2021, then surged by 59.8% to -$13.6 million in 2022, then jumped by 80.02% to -$2.7 million in 2023, then slipped by 29.63% to -$3.5 million in 2024, then advanced by 16.24% to -$2.9 million in 2025.
- The last three Net Cash Flow figures came in at -$2.9 million (Q4 2025), -$2.9 million (Q3 2025), and -$2.4 million (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.77 Bn | 131.91 Bn | 2.84 Bn | 652.90 Mn |
| 2 | Regeneron Pharmaceuticals | 86.74 Bn | 78.75 Bn | 3.93 Bn | -504.30 Mn |
| 3 | Argenx Se | 65.36 Bn | 60.17 Bn | 1.37 Bn | - |
| 4 | Moderna | 59.60 Bn | 54.47 Bn | 52.00 Mn | -183.00 Mn |
| 5 | BeOne Medicines | 42.10 Bn | 37.00 Bn | 1.53 Bn | 407.41 Mn |
| 6 | Alnylam Pharmaceuticals | 31.80 Bn | 28.49 Bn | 992.69 Mn | -496,000.00 |
| 7 | BioNTech SE | 28.13 Bn | 9.73 Bn | 668.28 Mn | -2.83 Bn |
| 8 | Insmed | 27.54 Bn | 26.38 Bn | 358.27 Mn | -37.14 Mn |
| 9 | Royalty Pharma | 27.31 Bn | 26.47 Bn | - | 225.59 Mn |
| 10 | CollPlant Biotechnologies | 4.12 Mn | 4.12 Mn | -243,000.00 | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -2.95 Mn |
| Dec 31, 2025 | -2.95 Mn |
| Sep 30, 2025 | -2.88 Mn |
| Sep 30, 2025 | -2.88 Mn |
| Jun 30, 2025 | -2.44 Mn |
| Jun 30, 2025 | -2.44 Mn |
| Dec 31, 2024 | -3.52 Mn |
| Dec 31, 2024 | -3.52 Mn |
| Sep 30, 2024 | -3.59 Mn |
| Sep 30, 2024 | -3.59 Mn |
| Jun 30, 2024 | -4.19 Mn |
| Jun 30, 2024 | -4.19 Mn |
| Mar 31, 2024 | -3.33 Mn |
| Mar 31, 2024 | -3.33 Mn |
| Dec 31, 2023 | -2.72 Mn |
| Dec 31, 2023 | -2.72 Mn |
| Sep 30, 2023 | 6.75 Mn |
| Sep 30, 2023 | 6.75 Mn |
| Jun 30, 2023 | -4.05 Mn |
| Jun 30, 2023 | -4.05 Mn |